Highbridge Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Highbridge Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-24,757	Closed	-$184K	–	1366
2016 Q3	$184K	Sell	24,757 -221,479	-90%	-$1.5M	﹤0.01%	1196
2016 Q2	$1.34M	Buy	+246,236	New	+$1.72M	0.02%	533
2015 Q3	–	Sell	-281,212	Closed	-$3.98M	–	1633
2015 Q2	$3.98M	Sell	281,212 -81,985	-23%	-$986K	0.05%	355
2015 Q1	$3.95M	Buy	363,197 +302,401	+497%	+$2.67M	0.05%	367
2014 Q4	$506K	Buy	+60,796	New	+$417K	0.01%	813
2014 Q3	–	Sell	-32,508	Closed	-$109K	–	1253
2014 Q2	$109K	Buy	+32,508	New	+$76.3K	﹤0.01%	1004

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Highbridge Capital Management's FOLD Position: Q4 2016 in Review

Highbridge Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2016, closing a stake of 24,757 shares — an estimated $184K sold.

Highbridge Capital Management first reported a position in FOLD in Q2 2014 and held it in 6 quarters. The position peaked at $3.98M in Q2 2015. 135 funds tracked by Wall St. Rank hold FOLD as of Q4 2016.

Highbridge Capital Management reported no remaining Amicus Therapeutics position as of Q4 2016 after selling out during the quarter.
Highbridge Capital Management sold 24,757 Amicus Therapeutics shares in Q4 2016, an estimated $184K.
Highbridge Capital Management first reported a position in Amicus Therapeutics in Q2 2014 and held it in 6 quarters.
Highbridge Capital Management's Amicus Therapeutics position peaked at $3.98M in Q2 2015.
135 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.